Biological
Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine clinical trials
- studies test it
- 29
- open now
- 1
- in phase 3
- 15
- first study started
- 1998
Keep track of what changes. Save the diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2007 (5)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 4 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 5
- Phase 3
- 15
- Phase 4
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 2
GlaxoSmithKline (23) · Sanofi Pasteur, a Sanofi Company (1) · Laval University (1) · Universiteit Antwerpen (1) · Merck Sharp & Dohme LLC (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1) · Pfizer (1)
Often tested with
Tested in the same studies.
PHiD-CV vaccine (4) · RIX4414 vaccine (3) · Acetaminophen (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Pediarix (2) · Meningococcal Vaccines (2) · Diphtheria-Tetanus-acellular Pertussis Vaccines (2) · DTaP-IPV-HB-PRP-T vaccine (1)
Studies
Open first, then newest update. How each study uses diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine is read from its arms, and is right about nine times in ten.
Testing it · 29
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesRecruitingPhase 3PfizerNCT07160244Written as Infanrix hexa
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT06647407Written as DTap-HepB-IPV-Hib vaccine
- Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old ChildrenCompletedPhase 4Laval UniversityNCT04294433Written as Infanrix-hexa
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and ToddlersCompletedPhase 4GlaxoSmithKlineNCT04535037Written as DTPa-HBV-IPV/Hib
- Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00624819Written as Infanrix hexa
- Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedPhase 4GlaxoSmithKlineNCT02853929Written as Infanrix hexa
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of AgeCompletedPhase 3GlaxoSmithKlineNCT00489554Written as Infanrix hexa
- Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccineCompletedPhase 3GlaxoSmithKlineNCT01353703Written as Infanrix hexa™
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedPhase 3GlaxoSmithKlineNCT00463437Written as Infanrix hexa
- Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in InfantsCompletedPhase 4GlaxoSmithKlineNCT00753649Written as Infanrix™ hexa
- Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT02096263Written as Infanrix hexa
- Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in ThailandCompletedPhase 4Universiteit AntwerpenNCT02408926Written as Infanrix hexa
- Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedPhase 4GlaxoSmithKlineNCT02422264Written as Infanrix hexa
- Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each VaccineCompletedPhase 3GlaxoSmithKlineNCT00508261Written as Infanrix™ hexa
- Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm InfantsCompletedPhase 3GlaxoSmithKlineNCT00390910Written as Infanrix hexa
- Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years OldCompletedPhase 2GlaxoSmithKlineNCT00196976Written as DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of AgeCompletedPhase 3GlaxoSmithKlineNCT00533507Written as Infanrix hexa
- Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib VaccineCompletedPhase 2GlaxoSmithKlineNCT00627458Written as Infanrix Hexa
- Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old ChildrenCompletedPhase 4GlaxoSmithKlineNCT00611559Written as Infanrix™ hexa
- Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B VaccineCompletedPhase 3GlaxoSmithKlineNCT00325143Written as DTPa-HBV-IPV/Hib
Given in every arm · 18 — diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine is usual care beside what is tested
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United KingdomCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03632720Written as Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)CompletedPhase 3Merck Sharp & Dohme LLCNCT04031846Written as Infanrix™ hexa
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib VaccinesCompletedPhase 3GlaxoSmithKlineNCT01144663Written as Infanrix™ hexa
- Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedPhase 2GlaxoSmithKlineNCT01453998Written as Infanrix hexa
- Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in VietnamCompletedPhase 3GlaxoSmithKlineNCT01153841Written as Infanrix hexa™
- Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT01616459Written as Infanrix hexa™
- COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00466947Written as Infanrix hexa
- Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.CompletedPhase 3GlaxoSmithKlineNCT00370396Written as Infanrix hexa
- Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT01204658Written as Infanrix Hexa (DTPa-HBV-IPV/Hib)
- Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic TreatmentCompletedPhase 4GlaxoSmithKlineNCT01235949Written as Infanrix hexa
- Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850ACompletedPhase 3GlaxoSmithKlineNCT00496015Written as Infanrix hexa.
- Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up ScheduleCompletedPhase 2GlaxoSmithKlineNCT00513409Written as Infanrix Hexa
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of AgeCompletedPhase 3GlaxoSmithKlineNCT00808444Written as Infanrix hexa
- Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose ScheduleCompletedPhase 3GlaxoSmithKlineNCT00307034Written as Infanrix hexa.
- V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)CompletedPhase 3Merck Sharp & Dohme LLCNCT00258154Written as Comparator: Infanrix(tm) Hexa
- Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 VaccineWithdrawnPhase 2GlaxoSmithKlineNCT01110044Written as Infanrix hexa™
- Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesCompletedPhase 2Novartis VaccinesNCT00721396Written as combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine
- Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®CompletedPhase 4PfizerNCT01392378Written as INFANRIX hexa
As the comparator · 21 — what is tested is compared with diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African ChildrenNot yet recruitingPhase 2GlaxoSmithKlineNCT07320716Written as Infanrix hexa
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and InfantsCompletedPhase 2GlaxoSmithKlineNCT06213506Written as DTPa-HBV-IPV+Hib
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsCompletedPhase 1/2GlaxoSmithKlineNCT05073003Written as INFANRIX HEXA
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsCompletedPhase 2GlaxoSmithKlineNCT06663436Written as Infanrix hexa
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedPhase 2GlaxoSmithKlineNCT01171989Written as Infanrix hexa™
- Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT00970307Written as Infanrix hexa™
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)CompletedPhase 3MCM Vaccines B.V.NCT01341639Written as INFANRIX™ hexa
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)CompletedPhase 3MCM Vaccines B.V.NCT01480258Written as INFANRIX™ hexa
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of AgeCompletedPhase 2GlaxoSmithKlineNCT00129116Written as Infanrix hexa ®
- Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedPhase 2GlaxoSmithKlineNCT01248884Written as Infanrix hexa™
- Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT01090453Written as Infanrix hexa™
- Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.TerminatedPhase 2GlaxoSmithKlineNCT00871741Written as Infanrix hexa
- Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedPhase 3Novartis VaccinesNCT00657709Written as Infanrix Hexa
- Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenCCompletedPhase 3GlaxoSmithKlineNCT00322335Written as Infanrix™ hexa
- Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC VaccineCompletedPhase 3GlaxoSmithKlineNCT00327184Written as Infanrix hexa
- Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00654901Written as Infanrix Hexa™
- Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00831753Written as DTaP-HB-IPV and Haemophilus influenzae type b
- Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00355654Written as DT3aP-HBs-IPV
- Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy InfantsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01444781Written as DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide
- A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American InfantsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01177722Written as DTaP-Hep B-IPV vaccine
Showing 20 of 21.